Compare Adaptive Biotechnologies Corp (ADPT) vs Old Dominion Freight Line Inc (ODFL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Old Dominion Freight Line Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.98 (market cap $3.33B), while Old Dominion Freight Line Inc trades at $216.51 (market cap $44.82B). The key difference: Old Dominion Freight Line Inc is far larger — about 13.5× Adaptive Biotechnologies Corp's market cap, and Old Dominion Freight Line Inc pays a 0.54% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | ODFL | |
|---|---|---|
Market Cap | $3.33B | $44.82B |
Sector | Health | Industrials |
52-Week High | $22.37 | $248.73 |
52-Week Low | $10.24 | $126.29 |
Enterprise Value | $3.19B | $44.58B |
Dividend Yield | — | 0.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ODFL trades at $215.51, down 0.98% today, with technical indicators showing a bearish trend near support at $214. The company maintains strong fundamentals with a Q1 2026 EPS beat of $1.14 versus $1.05 expected, though revenue declined to $5.5B in 2025. Valuation remains elevated with a P/E of 45.18 and P/S of 8.35, while profitability metrics like ROE of 23.33% and net margin of 18.46% highlight operational efficiency.
The outlook is mixed: analyst consensus targets $230.69 with 33% buy ratings, but near-term risks include Amazon's LTL expansion (Barron's, June 10, 2026) and high valuation concerns. Cash flow stability and debt-free balance sheet support long-term potential, though investors face headwinds from freight market volatility and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →
